

August 23, 2017

Dear Editors and Reviewers,

It has been our pleasure to receive your suggestions to clarify and improve our manuscript entitled: Neoadjuvant Therapy for Resectable Pancreatic Cancer.

We have revised the manuscript to address all the comments made by the four reviewers. Specifically, these are the changes made in the body of the manuscript:

- All the language and spelling errors have been addressed using several reiterations.
- We added a table 1 where we summarize the most common definitions for resectable, borderline and resectable pancreatic cancer.
- We added a paragraph to clarify how current retrospective studies have defined response to neoadjuvant therapy
- Table 2, was modified to avoid possible areas where the test was not clear enough (as commented by reviewer n.2)
- Reviewer n. Three stated that neoadjuvant therapy for treating unresectable pancreatic cancer might be a more important clinical question, which should be elaborated further. We did not change our manuscript as our primary objective was to analyze the current evidence on the use of neoadjuvant strategies for resectable pancreatic cancer. The reviewer seemed to have missed the entire point of our manuscript, and we did not agree with his comments.
- Reviewer n. Three also suggested that a meta-analysis should be considered. We disagree with this statement as there are no RCTs and the observational studies on this topic are very heterogeneous. Therefore, we do not support pooling data as this would not be good for the scientific point of view.
- Reviewer n. Three suggested that our references should be more recent. This point was not addressed as all the references in our manuscript are the most recent and published during the most recent years. We felt that the reviewer did not pay attention to the year of publication of all the references we cited.